390O - Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

F Barlesi,D.-W Kim,E.M Bertino,M.J Van Den Bent,H Wakelee,P.Y Wen,P Garrido Lopez,S Orlov,M Majem,M Mckeage,C.-J Yu,F.K Hurtado,P Cazorla Arratia,Y Song,F Branle,M Shi,L.Q Chow

doi:10.1093/annonc/mdz243

390O - Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

F Barlesi, D.-W Kim + Show 15 more

Open Access

https://doi.org/10.1093/annonc/mdz243

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 9	License type: publisher-specific-oa

Affiliation: Aix-Marseille University, Seoul National University Hospital, James Cancer Hospital, Stanford University, Dana-Farber Cancer Institute, Hospital de Sant Pau, University of Auckland, National Taiwan University Hospital, University of Washington

#On Overall Response Rate #Non-small Cell Lung Cancer Pts + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

390O - Efficacy and safety of ceritinib in ALK-positive non-small cell lung cancer (NSCLC) patients with leptomeningeal metastases (LM): Results from the phase II, ASCEND-7 study

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.